

STUDY OF INTERACTION BETWEEN TIGECYCLINE AND SULBACTAM

ABSTRACT

Drug interactions can have desired, reduced or unwanted effects. The probability of interactions increases with the number of drugs taken. Side effects or therapeutic drug interactions can increase or decrease the effects of one or two drugs. "Failure may result from clinically meaningful interactions." Clinicians rarely use foreseeable drug-drug interactions to produce the desired therapeutic effect. For example, when we consider two drugs each causing, peripheral neuropathy increases the likelihood of neuropathy occurrence. In this study geometry optimizations of tigecycline and sulbactam drugs and their combination have been carried out with the evaluation of B3LYP/6-311G (d,p), B3LYP/6-311G (2d,2p) levels, and the reaction mechanism at semi empirical PM6, which was parameterized for biochemical systems and B3LYP/6-311G (d,p) levels. The main objective of the study is to understand the interaction of sulbactam with tigecycline, to describe energetic condition of bond formation and electronic structure (orders of the broken and formed bonds). The reaction mechanisms of sulbactam with tigecycline have been studied as stepwise and concerted mechanisms using semi-empirical PM6 and B3LYP/6-311G (d,p) levels

12
13
14
15
16
17
18
19

Keywords: Tigecycline and Sulbactam, Semi-empirical, PM6, B3LYP

1. INTRODUCTION

Sulbactam, is the β -lactamase inhibitors in clinical use. Sulbactam sodium (SBT) named as 4-thia-1-azabicyclo [3.2.0] heptane 2-carboxylic acid, 3,3-dimethyl-7-oxo-4,4 dioxo sodium salt, and it is official in the British Pharmacopoeia [1].

20
21
22
23
24
25
26

Tigecycline representing a new class of antimicrobials known as glycylicyclines is (4S,4aS,-5aR,12aS)-9-(2-tert-butylaminoacetyl-amino)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,-6,11,12a-octahydronaphthacene-2-carboxamide [2] and it has more potent activity against a variety of tetracycline-resistant and multidrug-resistant Gram-positive and Gram-negative bacterial pathogens. Because of its microbiological, pharmacodynamic and pharmacokinetic properties, this antibiotic has been evaluated as monotherapy for serious infections in human clinical trials [3,4].

27
28
29
30
31

The effects of meropenem, imipenem, sulbactam, colistin, and tigecycline, alone or in combination, on biofilm-embedded were investigated due to difficulty in destruction of *Acinetobacter baumannii* biofilms [5] and reported that **significant** decreases in the maximum biofilm thickness were observed after exposure to meropenem and imipenem. Meropenem plus sulbactam significantly decreased the biomass and mean thickness and increased the

32 roughness coefficient of biofilms, but sulbactam plus tigecycline only decreased the maximum
33 and mean biofilm thickness compared to any of these agents used alone.

34 The clinical efficacy between salvage antimicrobial regimen consisting of tigecycline plus
35 extended-infusion imipenem/cilastatin (TIC) and regimen of sulbactam plus imipenem/cilastatin
36 (SIC) for patients with ventilator-associated pneumonia and pneumonic bacteremia due to
37 extensively drug-resistant (XDR) *Acinetobacter baumannii* (Ab) isolates were compared and
38 determined the correlation of results of in vitro tigecycline **imipenem** synergy test with clinical
39 efficacy [6].

40 Numerous studies have shown that combinations of tigecycline and sulbactam are promising
41 treatment options for MDR *A. baumannii*. They tested ten clinical isolates of *A. baumannii*
42 sensitive colistin and tigecycline synergistic effects of tigecycline and sulbactam and reported
43 that Tigecycline MIC values decreased 2-4 fold with sulbactam and this combination resulted in
44 synergy or partial synergy in 50% of the isolates [7].

45 In vitro study conducted on 25 XDR *A. baumannii*, it has been shown that sulbactam plus
46 tigecycline provides synergy or additional effects at 84% of stains and no antagonism [8]

47 **Quantum chemical calculations were used to analyze the formation of a peptide bond between**
48 **phenylalanine and Ceftriaxone molecules [9]. The reaction mechanism of phenyl alanine with**
49 **meropenem have been studied as stepwise mechanism by means of PM6-semi-empirical [10].**

50 In this work, we present a density functional theoretical and semi-empirical studies on the
51 mechanism of the reaction between the sulbactam, and tigecycline. The calculated reaction
52 mechanism is presented and discussed in a general way.

53

54 **2. MATERIAL AND METHODS**

55

56 **2.1. COMPUTATIONAL DETAILS**

57 All the reactants, products and transition states have been optimized again within the semi-
58 empirical method-pm6 and density functional theory (DFT) framework, by using the B3LYP
59 functional. This functional is based on Becke's three-parametrization adiabatic connection
60 method (ACM) and consists of a combination of Slater [11] Hartree-Fock, [12] and Becke [13]
61 exchange functionals, the Vosko, Wilk, and Nusair (VWN) local correlation functional, [14] and
62 the Lee, Yang, and Parr [15] nonlocal correlation functional. The IRC have been computed
63 automatically using intrinsic reaction coordinate (IRC), following algorithms. IRC was proposed
64 by Fukui in 1970 as a pathway of chemical reactions, 1, 2, the steepest descent path weighted
65 predominantly on the potential energy surface (PES), starting from the transition (TS), ie the
66 first rank saddle point. Starting from nonstationary structures, the mass - weighted steepest
67 descent path is called meta - IRC.

68 **The reaction mechanism between tigecycline and sulbactam were performed with the**
69 **theoretical method of PM6 and B3LYP functional with full geometry optimization and E_{HOMO} and**
70 **E_{LUMO} for tigecycline, sulbactam and tigecycline sulbactam were calculated with the B3LYP/6-**
71 **311G(d,p) level and the B3LYP/6-311G(2d,2p) level.**

72 The calculations have been carried out with the GAUSSIAN 09 series of programs [16].

73


74 **3. RESULTS AND DISCUSSION**

75

76 The relative energies of the ground and transition states in the addition of tigecycline to
77 sulbactam in gas media are presented in Figure 1 that the reactant located on the left side in

78 the diagram reaches the product on the right side via several intermediates and transition
79 states. These profiles were obtained from the results of analysis of the PES by relaxed
80 scanning over the reaction coordinate using the B3LYP/6311G(d,p) method.


81 Two transition states for stepwise mechanism are depicted as saddle points, and the energies
82 required to go over each barrier (ΔG_1 , ΔG_2) are called activation energies. One transition state
83 for concerted mechanism is depicted as saddle point and activation energy is ΔG_3 .
84



85
86
87
88
89
90
91
92
93
94
95

Fig. 1. Reaction energy diagram

The concerted and stepwise mechanisms for the bond formation are illustrated with the
optimized structures of the reactants, the three transition states and one intermediate, and for
products calculated with B3LYP/6-311G(d,p) level in Fig 2.






Fig. 2 Reaction mechanism between sulbactam and tigecycline

96
 97
 98
 99 In this reaction we considered the reaction between the HOMO of tigecycline and the LUMO of
 100 sulbactam. For both the B3LYP and PM6 success was achieved when the interaction of
 101 tigecycline N lone pair with the carbonyl centre of sulbactam was performed. When considering
 102 both the charge interaction and most likely the HOMO/LUMO interactions led to the conclusion
 103 that glycine react with sulbactam by nucleophilic attack of tigecycline nitrogen (N) lone pair on
 104 the carbonyl carbon C7 of sulbactam considered the reaction between the HOMO of tigecycline
 105 and the LUMO of sulbactam. HOMO, LUMO, electron density of the optimized structures of
 106 reactants, IN, transition states and products are shown in Figure 3.

107 Electrostatic potential maps enable us to visualize the charge distributions of molecules and
 108 charge related properties of molecules. They also allow us to visualize the size and shape of
 109 molecules. Different colors represent the different values of the electrostatic potential at the
 110 surface. Potential increases in the ordered (most negative) < orange < yellow < green < blue
 111 (most positive). (MEP) surfaces are plotted over the optimized electronic structure of reactants,
 112 the three transition states and one intermediate, and for products calculated with B3LYP/6-
 113 311G(d,p) level in Fig 3. MEP surface directly provides information about the electrophilic
 114 (electronegative charge region) and nucleophilic (most positive charge region) regions.


115 In general, two molecules which are either the two atoms that have highest and opposite
 116 charges or two atoms that have a highest electron densities in their highest occupied or lowest
 117 unoccupied atomic molecular orbital's interact each other.


118 In the first step nitrogen lone pair of one amino group belonging to tigecycline attacks the
 119 carbonyl carbon atom of the sulbactam, molecule leading to the formation of C-N bond which is
 120 the addition step. The second step is the elimination of water molecule.

121 For the stepwise process, an intermediate INT1 is separated from reactants by 19.21 kcal/mol
 122 barrier at transition state TS1 and from products by 34.64 kcal/mol at transition state TS2. For
 123 concerted process 3 is separated from reactants by 58.43 kcal/mol at transition state TS3.
 124 Vibration analysis was performed for the reactants, intermediates, transition states and final
 125 molecules. We found a negative imaginary frequency which is characteristic of an ordinary TS
 126 for transitional states (TS). Generally, an imaginary frequency for TS is the first order saddle.
 127 The imaginary frequencies for TS1 and TS2 in the stepwise process are -338 cm⁻¹ and -1655
 128 cm⁻¹, and for concerted mechanism TS3 is -970 cm⁻¹.

129 The reacting molecules tigecycline and sulbactam (1+2). being far from each other (N1- C7 =
 130 3.000 Å) have a summary energy -1973192 kcal/mol with the calculation B3LYP/6-311G(d,p)
 131 level for both tigecycline and sulbactam.

132 From Table 1 it was found that the bonds between N-H is 1.01 Å and 1.03 Å for B3LYP and
133 PM3 respectively and bond length for O=C is 1.20 Å and 1.21 Å, respectively while sulbactam
134 and tigecycline were sufficiently far apart, the bonds between N-H in the course of reaction
135 increase by 1.32 Å and 0.11 Å for B3LYP and PM3 respectively. While for O=C it increases by
136 0.03 Å and 0.19Å for B3LYP and PM3 respectively. All these are due to pulling of electron by
137 the reacting atoms in the transition state (TS1). The N1-C7 bond between tigecycline and
138 sulbactam is partially formed at the TS1. N1-C7 bond length with the calculation B3LYP in the
139 course of reaction changes to 2.15 Å, 1.49 Å, 1.50 Å and 1.39 Å at TS1, IN, TS2 and 3,
140 respectively.
141





142 **Fig. 3 ESP, HOMO, LUMO of reactants, intermediate, transition states and products**

143

144

145 The distance between **the carbon** and nitrogen involved in the formation of the new N–C single
 146 bonds in the synchronous TS1 and in IN is found to be 2.15 Å and 1.49 Å for B3LY/6-311G(d,p)
 147 and 3.32 Å and 1.50 Å for PM6 level. The distance between **the carbon** and nitrogen involved in
 148 the formation of the new N–C single bonds in TS3 is found to be 2.13 Å and 1.49 Å for B3LY/6-
 311G(d,p) and PM6 levels.

149

150 Now let's consider TS2. The C7-O9 distance of 1.65 Å and 1.62 Å for B3LY/6-311G(d,p) and
 151 PM7 levels, respectively compared to the approximation value of 1.350 Å for a single bond,
 does not suggest any significant bonding between those two atoms.

152

153 The Mulliken charges of atom C7 at 1+2, TS3 and 3 for calculations with B3LY/6-311G(d,p) are
 154 0.38 e⁻, 0.0.38 e⁻, 0.41 e⁻, respectively; charges on atom N1 at 1+2, TS3 and 3 are -0.50 e⁻, -0.65
 155 e⁻, -0.38 e⁻, and those of atoms O8 and O9 are -0.33 e⁻, -0.31 e⁻ for 1+2, -0.23 e⁻, -0.543 e⁻ for TS3
 156 and -0.38 e⁻, -0.50 e⁻ for 3. Different orbitals overlapping cause changing of Mulliken charges.

157

158 **Table 1. Bond Lengths and Mulliken charges of the reactants, the three transition states**
 159 **and one intermediate, and products**

Atom Numbers	B3LYP/6-311g(d,p)						PM6					
	1+1	TS1	IN	TS2	TS3	3	1+1	TS1	IN	TS2	TS3	3
Bond Lengths (Å)												
N ₁ -C ₄	1.40	1.29	1.39	1.37	1.38	1.41	1.41	1.35	1.42	1.41	1.44	1.42
C ₄ -C ₆	1.50	1.47	1.49	1.49	1.50	1.49	1.48	1.44	1.47	1.48	1.47	1.47
C ₄ -O ₅	1.21	1.32	1.23	1.24	1.21	1.21	1.22	1.31	1.23	1.23	1.24	1.22
N ₁ -H ₂	1.01	2.33	2.33	2.32	1.04	3.73	1.03	1.14	2.54	2.55	1.81	3.43
N ₁ -H ₃	1.01	1.02	1.01	1.02	1.01	1.01	1.01	1.00	1.03	1.03	1.05	1.04
N ₁ -C ₇	3.00	2.15	1.49	1.50	2.13	1.39	3.50	3.32	1.50	1.50	1.56	1.42
C ₇ -O ₈	1.20	1.23	1.38	1.25	1.18	1.22	1.21	1.21	1.40	1.25	1.42	1.22
C ₇ -O ₉	1.35	1.35	1.39	1.65	1.70	2.80	1.37	1.37	1.41	1.64	1.38	2.80
O ₉ -H ₁	0.97	0.97	0.97	1.80	2.40	1.82	1.00	1.00	0.99	1.89	0.99	4.07
O ₈ -H ₂	2.06	1.64	0.98	1.04	1.55	0.96	2.00	1.99	1.02	1.03	1.07	0.97
O ₈ -H ₁₁	2.31	2.28	2.27	0.98	0.97	0.97	2.37	2.37	2.25	1.04	2.32	1.01
C ₇ -C ₁₁	1.53	1.53	1.56	1.55	1.56	1.53	1.53	1.53	1.58	1.57	1.56	1.54
C ₁₁ -N ₁₂	1.47	1.47	1.46	1.48	1.46	1.46	1.48	1.47	1.47	1.47	1.48	1.47
C ₁₁ -C ₁₃	1.56	1.57	1.57	1.55	1.56	1.57	1.55	1.55	1.55	1.55	1.56	1.56
Mulliken charges (e ⁻)												
O ₅	-0.32	-0.32	-0.39	-0.40	-0.37	-0.34	-0.57	-0.71	-0.57	-0.57	-0.56	-0.57
N ₁	-0.50	-0.55	-0.45	-0.50	-0.65	-0.38	-0.61	-0.54	-0.64	-0.64	-0.62	-0.56
C ₆	-0.13	-0.07	-0.13	-0.15	-0.13	-0.14	-0.63	-0.64	-0.62	-0.62	-0.69	-0.70
C ₄	0.32	0.36	0.43	0.42	0.40	0.40	0.69	0.64	0.73	0.73	0.73	0.77
H ₂	0.24	0.22	0.24	0.27	0.23	0.24	0.27	0.30	0.29	0.29	0.31	0.31
H ₃	0.23	0.28	0.27	0.31	0.33	0.28	0.29	0.37	0.39	0.37	0.45	0.34
O ₉	-0.31	-0.32	-0.37	-0.38	-0.45	-0.50	-0.53	-0.53	-0.56	-0.57	-0.72	-0.66

O ₈	-0.33	-0.45	-0.39	-0.46	-0.23	-0.38	-0.52	-0.50	-0.60	-0.68	-0.60	-0.52
N ₁₂	-0.33	-0.33	-0.37	-0.33	-0.35	-0.34	-0.46	-0.45	-0.46	-0.46	-0.45	-0.39
C ₁₃	-0.51	-0.51	-0.45	-0.48	-0.48	-0.49	-0.28	-0.29	-0.27	-0.26	-0.27	-0.28
C ₁₁	0.38	0.06	0.04	-0.03	0.07	0.05	-0.05	-0.04	-0.06	-0.05	-0.04	-0.08
C ₇	0.38	0.46	0.39	0.46	0.38	0.41	0.63	0.63	0.67	0.67	0.67	0.62
H ₁₁	0.27	0.25	0.25	0.28	0.28	0.28	0.34	0.34	0.35	0.44	0.34	0.38

160

161 Substantial characters of materials are obtained with the quantum chemical calculations.
 162 Computational calculation is an alternate choice due to difficulty to measure hyperpolarizability
 163 directly, The first order-hyperpolarizability and related properties of sulbactam and tigecycline
 164 and sulbactam- tigecycline were calculated using B3LYP/6-311G(d,p) basis set, based on the
 165 finite field approach. The mean first-order hyperpolarizability can be calculated using the
 166 equation 1.

$$167 \quad \beta_{\text{total}} = \sqrt{((\beta_{xxx} + \beta_{xyy} + \beta_{xzz})^2 + (\beta_{yyy} + \beta_{yzz} + \beta_{yxx})^2 + (\beta_{zzz} + \beta_{zxx} + \beta_{zyy})^2)} \quad (1)$$

168 The DFT/6-31G (d,p) calculated first hyperpolarizability values (β) of for tigecycline-sulbactam,
 169 tigecycline, sulbactam are equal to 20.427×10^{-30} , 1.398×10^{-30} , 10.954×10^{-30} esu.

170 According to Koopman's theorem [17] chemical hardness, electronegativity and chemical
 171 potential can be defined as:

$$172 \quad \eta = 1/2 (E_{\text{LUMO}} - E_{\text{HOMO}}) \quad (2)$$

$$173 \quad \mu = -\chi = 1/2 (E_{\text{HOMO}} + E_{\text{LUMO}}) \quad (3)$$

174 Global softness which is one of the most important reactivity descriptors is defined as the
 175 inverse of global hardness as in the given following equation: [18, 19]

$$176 \quad \sigma = 1/\eta \quad (4)$$

177 Electrophilicity (ω) is another parameter and indicates tendency of the molecule to accept
 178 electrons. Electrophilicity index explain the electrophilic and nucleophilic behavior of molecules.
 179 Electrophilicity index is defined via equation 5 [20]. A good electrophile means high
 180 electronegativity (or chemical potential) and low chemical hardness values.

$$181 \quad \omega = \mu^2/2\eta \quad (5)$$

182 The DFT/6-311G(d,p) calculated electrophilicity values (ω) for tigecycline-sulbactam,
 183 tigecycline, sulbactam are equal to 5.147, 2.671, 4.915. The values are the largest for the
 184 tigecycline-sulbactam than for the alone tigecycline and alone sulbactam. The established order
 185 is as follows: tigecycline-sulbactam > tigecycline > sulbactam.

186 Nucleofugality (ΔE_n), Electrofuqality (ΔE_e) are useful theoretical descriptors and may be
 187 calculated with equation 6 and 7.

$$188 \quad \Delta E_n = -A + \omega = (\mu + \eta)^2/2\eta \quad (6)$$

$$189 \quad \Delta E_e = I + \omega = (\mu - \eta)^2/2\eta \quad (7)$$

190 The results in Table 2 establish the influence of tigecycline, sulbactam and tigecycline-
 191 sulbactam on the first hyperpolarizability and the other descriptors calculated with B3LYP(6-

192 311G(d,p) and B3LYP(6-311G(2d,2p) levels. The values are the largest for the tigecycline-
 193 sulbactam than for the alone tigecycline and alone sulbactam. The established order is as
 194 follows: sulbactam > tigecycline > tigecycline-sulbactam

195 The lowest unoccupied molecular orbital - E_{LUMO} , The highest occupied molecular orbital
 196 energies- E_{HOMO} , hardness, softness, electronegativity, energy gap, chemical potential,
 197 electrophilicity index, nucleofugality, electrofugality are given in Table 2.

198 Eventual charge transfer interaction is taking place within the molecule is explained with the
 199 HOMO and LUMO energy gap. Hardness defined the gap between the HOMO and LUMO
 200 orbital energies is associated with the stability of the chemical. The gap energies between
 201 E_{HOMO} and E_{LUMO} for tigecycline, sulbactam and tigecycline-sulbactam calculated with the
 202 B3LYP/6-311G(d,p) level are 3.286 eV, 6.579 eV, and 3.379 eV, respectively and 3.347 eV,
 203 6.599 eV and 3.397 eV with the B3LYP/6-311G(2d,2p) level. As shown in table 2, the
 204 compound that has the highest HOMO energy is the tigecycline ($E_{HOMO} = -5.661$ eV). This higher
 205 energy allows it to be the best electron donor. The compound that has the lowest LUMO energy
 206 is the compound tigecycline-sulbactam ($E_{LUMO} = -2.481$ eV) which signifies that it can be the best
 207 electron acceptor.

208 . Table 2. Some descriptors for tigecycline, sulbactam and tigecycline sulbactam

209

	tigecycline		sulbactam		tigecycline-sulbactam	
	6-311 G(d,p)	6-311 G(2d,2p)	6-311 G(d,p)	6-311 G(2d,2p)	6-311 G(d,p)	6-311 G(2d,2p)
E_{LUMO}	-2.376	-2.342	-0.903	-0.829	-2.481	-2.433
E_{HOMO}	-5.661	-5.689	-7.482	-7.428	-5.859	-5.831
ΔE	3.286	3.347	6.579	6.599	3.379	3.397
η	1.643	1.673	3.290	3.299	1.689	1.699
S	0.304	0.299	0.152	0.152	0.296	0.294
χ	4.018	4.016	4.192	4.128	4.170	4.132
μ	-4.018	-4.016	-4.192	-4.128	-4.170	-4.132
ω	4.915	4.818	2.671	2.583	5.147	5.025
ΔE_{\dots}	1.717	1.639	0.124	0.104	1.822	1.743
ΔE	4.093	3.982	1.026	0.933	4.303	4.176
$\beta(10^{-30}$ esu)	10.954	10.873	1.398	2.082	20.427	20.120

210

211 4. CONCLUSION

212

213 The reaction is nucleophilic in nature in which the nitrogen lone pair of tigecycline attacks the
 214 carbonyl carbon (C7) of sulbactam to form tigecycline- sulbactam adduct. The two methods are
 215 in good agreement with one another since they produced two transition states and one
 216 intermediate for stepwise mechanism and one transition for concerted mechanism.

217 The HOMO–LUMO calculations show that the energy gap increases with the combination of
218 tigecycline- sulbactam. Some quantum chemical descriptors such as, energy gap, hardness,
219 softness, electronegativity, chemical potential, electrophilicity, nucleofugality, electrofugality
220 were calculated and compared among themselves.

221 REFERENCES

222

- 223 1. B. Pharmacopoeia. British Pharmacopoeia Commission London; the Department of Health.
224 Social Services and Public Safety. 2013;1:719-20.
- 225 2. Hoffmann M, DeMaio W, Jordan RA, Talaat R, Harper D, Speth J et al. Metabolism,
226 Excretion, and Pharmacokinetics of [¹⁴C]Tigecycline, a First-In-Class Glycylcycline Antibiotic,
227 after Intravenous Infusion to Healthy Male Subjects. *Drug Metabolism and Disposition*.
228 2007;35(9):1543-53.
- 229 3. Chopra I. Glycylcyclines: third-generation tetracycline antibiotics. *Curr Opin Pharmacol*.
230 2001;1(5):464-9.
- 231 4. Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, et al. The
232 glycylcyclines: a comparative review with the tetracyclines. *Drugs*. 2004;64(1):63-88.
- 233 5. Wang YC, Kuo SC, Yang YS, Lee YT, Chiu CH, Chuang MF, et al. Individual or Combined
234 Effects of Meropenem, Imipenem, Sulbactam, Colistin, and Tigecycline on Biofilm-Embedded
235 *Acinetobacter baumannii* and Biofilm Architecture. *Antimicrob Agents Chemother*.
236 2016;60(8):4670-6.
- 237 6. Jean SS, Hsieh TC, Hsu CW, Lee WS, Bai KJ, Lam C. Comparison of the clinical efficacy
238 between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against
239 ventilator-associated pneumonia with pneumonic extensively drug-resistant *Acinetobacter*
240 *baumannii* bacteremia, and correlation of clinical efficacy with in vitro synergy tests. *J Microbiol*
241 *Immunol Infect*. 2016;49(6):924-33.
- 242 7. Cai Y, Bai N, Liu X, Liang B, Wang J, Wang R. Tigecycline: Alone or in combination?.
243 *Infectious Diseases*. 2016;48(7):491-502.
- 244 8. Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS. Effectiveness and
245 safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial
246 infections. *Int J Antimicrob Agents*. 2014;44(1):1-7.
- 247 9. Sayiner HS, Kandemirli F, The Reaction Mechanism Study Of Ceftriaxone And
248 Phenylalanine. *Journal of International Research in Medical and Pharmaceutical Sciences*,
249 2015;9(2):83-90.
- 250 10. Sayiner HS, Kandemirli F, The Interaction Study with Meropenem and Phenylalanine.
251 *International Journal of Science and Engineering Investigations*. 2017;6(62):114-117.
- 252 11. Slater JC. *Quantum Theory of Molecular and Solids*. McGrawHill. New York, 1974; Vol. 4.f
- 253 12. Fock VZ. *Physic* 1930;61:126.
- 254 13. Becke AD. Density-functional exchange-energy approximation with correct asymptotic
255 behavior. *Phys Rev. A* 1988;38:3098.
- 256 14. Vosko SH, Wilk L, Nusair M. Accurate spin-dependent electron liquid correlation energies
257 for local spin density calculations: a critical analysis. *Canadian Journal of Physics*,
258 1980;58(8):1200-11.
- 259 15. Lee C, Yang W, Parr. Development of the Colle-Salvetti correlation-energy formula into a
260 functional of the electron density. *Phys. Rev. B* 1988;37:785.
- 261 16. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman, J. R, et al.
262 Gaussian Inc. Wallingford CT. 2009.
- 263 17. Koopmans T. Über die Zuordnung von Wellenfunktionen und Eigenwerten zu den Einzelnen
264 Elektronen Eines Atoms. *Physica*. 1934;1(1-6):104-13. German.
- 265 18. Yang W, Lee C, Ghosh SK, Molecular softness as the average of atomic softnesses:
266 companion principle to the geometric mean principle for electronegativity equalization, *J. Phys*
267 *Chem*. 1985;89(25):5412-14.

- 268 19. YangW, Parr RG. Hardness, softness, and the fukui function in the electronic theory of
269 metals and catalysis. Proc Natl Acad Sci. 1985;82(20):6723-6.
270 20. Parr RG, Sventpaly L, Liu S. Electrophilicity Index. J Am Chem Soc 1999;121(9):1922-4.

UNDER PEER REVIEW